HERA-LIGAND Trademark

Trademark Overview


On Wednesday, May 8, 2019, a trademark application was filed for HERA-LIGAND with the United States Patent and Trademark Office. The USPTO has given the HERA-LIGAND trademark a serial number of 79262795. The federal status of this trademark filing is REGISTERED as of Tuesday, September 8, 2020. This trademark is owned by Apogenix AG. The HERA-LIGAND trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific services, namely, scientific and pharmaceutical research in the field of oncology and immunology relating to trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific and technological services, namely, protein design and protein engineering in the field of oncology and immunology relating to trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific consulting services in the field of protein design and protein engineering regarding trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety and providing scientific information in the field of protein design and protein engineering regarding trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety
hera-ligand

General Information


Serial Number79262795
Word MarkHERA-LIGAND
Filing DateWednesday, May 8, 2019
Status700 - REGISTERED
Status DateTuesday, September 8, 2020
Registration Number6144135
Registration DateTuesday, September 8, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 24, 2020

Trademark Statements


Goods and ServicesScientific services, namely, scientific and pharmaceutical research in the field of oncology and immunology relating to trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific and technological services, namely, protein design and protein engineering in the field of oncology and immunology relating to trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific consulting services in the field of protein design and protein engineering regarding trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety and providing scientific information in the field of protein design and protein engineering regarding trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 16, 2019
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameApogenix AG
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDE

Party NameApogenix AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDE

Party NameApogenix AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDE

Trademark Events


Event DateEvent Description
Thursday, July 11, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, July 16, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, July 20, 2019APPLICATION FILING RECEIPT MAILED
Monday, July 22, 2019ASSIGNED TO EXAMINER
Tuesday, July 23, 2019NON-FINAL ACTION WRITTEN
Wednesday, July 24, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 20, 2019REFUSAL PROCESSED BY MPU
Wednesday, August 21, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, September 6, 2019REFUSAL PROCESSED BY IB
Tuesday, February 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 7, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 7, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 7, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 4, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 24, 2020PUBLISHED FOR OPPOSITION
Tuesday, March 24, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 23, 2020ASSIGNED TO PETITION STAFF
Wednesday, February 12, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 21, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Thursday, May 28, 2020TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, June 23, 2020POST PUBLICATION AMENDMENT - ENTERED
Tuesday, December 8, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Monday, December 28, 2020FINAL DISPOSITION PROCESSED
Monday, December 28, 2020FINAL DISPOSITION NOTICE SENT TO IB
Friday, January 15, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, September 8, 2025COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, December 24, 2021NEW REPRESENTATIVE AT IB RECEIVED
Sunday, August 2, 2020EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, September 8, 2020REGISTERED-PRINCIPAL REGISTER